Start the conversation
All three indexes are in the red this afternoon, but there are still hot stocks today soaring as much as 130%.
Initial public offerings (IPOs) took center stage Friday, with five debuts. It would have been six if Globoforce hadn't postponed its IPO (citing unfavorable market conditions).
Yet plenty other stocks were also making news. Following are 12 of Friday's hot stocks to watch.
Today's Hot Stocks List
A10 Networks Inc. (NYSE: ATEN) shares rose 7% to a high of $16.50 intraday in its first day of trading. The San Jose, Calif. networking solutions company priced 12.5 million shares at $15. That was at the high end of the $13 to $15 range.
Amber Road Inc. (NYSE: AMBR), another new issue, soared 32% to a high of $17.90 intraday after it debuted. The East Rutherford, N.J. global trade management solution company priced 7,391,565 shares at $13, above the expected range of $10.50 to $12.
AVEO Pharmaceuticals Inc. (Nasdaq: AVEO) jumped 15% to $1.88 after regaining worldwide rights from Biogen Idec Inc. (Nasdaq: BIIB). The rights are in regard to AV-203, an antibody that reportedly has broad therapeutic potential for the treatment of cancer and other diseases. Last May, AV-203 successfully completed a phase 1 safety study that showed no dose-limiting toxicities across an entire dose range, up to and including the maximum dose of 20 mg/kg. Results from that study are expected to be presented this year. Biogen shares slipped 5%.
Borderfree Inc. (Nasdaq: BRDR) shares surged nearly 30% intraday to $21.25 in its first day trading as a public company. The NYC-headquartered cross-border solutions company priced 5 million shares at $16, the high end of the $14 to $16 expected range.
Endocyte Inc. (Nasdaq: ECYT) shares surged as much as 130% to a new 52-week high of $33.70 intraday. Gains followed reports that ECYT's experimental cancer drug, vintafolide, when used in tandem with chemotherapy, boosted survival rates in patients with non-recurrent lung cancer. That prompted RBC Capital Markets to suggest the company could become an attractive takeover target.